ClinicalTrials.gg
TerminatedNCT03652259Updated Jan 20, 2026

Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-Sarcoglycan Deficiency)

A Phase 1/2 interventional study of SRP-9003 in Limb-Girdle Muscular Dystrophy, Type 2E, sponsored by Sarepta Therapeutics, Inc.. Terminated at 1 site in United States. Open to participants aged 4 Years to 15 Years. Per ClinicalTrials.gov, last updated 2026-01-20.

Sponsored by Sarepta Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment

How we know

Why this study was terminated
Study is being terminated due to a business decision.

From the registry’s dates

  • Primary completion was Jan 2025, 1 year 10 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jan 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
6
Allocation
Non-randomized
Ages
4 Years to 15 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Muscular Dystrophies, Limb-Girdle with a site in United States — 3 open to participants now, 9 under way, 1 of them phase 3. Muscular Dystrophies, Limb-Girdle · United States.

Enrollment
12th of 17
6 · median 11
Started
2018
with 1 other
Phase 1/2
5 of 30
none open now
Registered
14th of 30
by date
Lead sponsor
8 of 30
Sarepta Therapeutics, Inc.

Among the 30 studies in Muscular Dystrophies, Limb-Girdle with a site in United States, this one is the 12th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2018, is one of 5 in phase 1/2, and was the 14th registered.

Muscular Dystrophies, Limb-Girdle

47 studies on the registry are indexed under Muscular Dystrophies, Limb-Girdle; 10 are open to participants now.

Browse Muscular Dystrophies, Limb-Girdle studies →

Open to participants now

3 of the 30 studies in Muscular Dystrophies, Limb-Girdle with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Muscular Dystrophies, Limb-Girdle studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.

This study: 4 Years to 15 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Muscular Dystrophies, Limb-Girdle with a site in United States, or all of them as a file.
02

Study summary

The proposed clinical trial is the first-in-human, single-center, open-label, gene delivery study of SRP-9003 (bidridistrogene xeboparvovec) in participants with LGMD2E.

03

Conditions studied

  • Limb-Girdle Muscular Dystrophy, Type 2E

Keywords

  • limb girdle muscular dystrophy
  • LGMD2E
  • beta-sarcoglycan
  • gene transfer
  • adeno-associated virus
  • LGMDR4
04

Who can participate

Ages eligible
4 Years to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females of any ethnic group
  • β-SG deoxyribonucleic acid (DNA) gene mutations at both alleles
  • Weakness demonstrated based on history of difficulty in running, jumping and climbing stairs
  • A 100 meter walk/run (MWR) test result: ≥40 % of predicted for age-, height-, gender-, and weight-matched healthy controls at the screening visit

Exclusion criteria

EXCLUSION CRITERIA

  • Active viral infection based on clinical observations
  • Cardiac magnetic resonance imaging (MRI) determined (LVEF) \<40%
  • Serological evidence of (HIV), , or infection
  • Diagnosis of (or ongoing treatment for) an disease
  • Abnormal laboratory values considered
  • Concomitant illness or requirement for chronic drug treatment that, in the opinion of the Principal Investigator, creates unnecessary risks for gene transfer.

Other inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Cohort 1: SRP-9003

    Participants will receive a single intravenous (IV) infusion of SRP-9003 at a prespecified dose.

    Genetic: SRP-9003

  • Experimental
    Cohort 2: SRP-9003

    Participants will receive a single IV infusion of SRP-9003. Dose will be determined based on the findings from Cohort 1.

    Genetic: SRP-9003

Interventions

  • GeneticSRP-9003

    SRP-9003 will be administered through a single systemic injection.

    Also known as: LGMD2E vector, bidridistrogene xeboparvovec

06

What researchers measure

Primary outcomes

  1. Number of Treatment-Emergent Adverse Events (AEs) and Treatment-Emergent Serious Adverse Events (SAEs)

    Time frame: Baseline up to 7 years

Secondary outcomes

  1. Change From Baseline in Quantity of Beta-Sarcoglycan (β-SG) Protein Expression at Day 60, as Measured by Western Blot

    β-SG gene expression levels will be quantified by Western Blot and compared between pre and post muscle biopsies.

    Time frame: Baseline, Day 60

  2. Change From Baseline in Quantity of β-SG Protein Expression at Day 60, as Measured by Immunofluorescence

    β-SG gene expression levels will be quantified by immunofluorescence and compared between pre and post muscle biopsies.

    Time frame: Baseline, Day 60

  3. Change From Baseline in Quantity of β-SG Protein Expression at Day 60, as Measured by Immunohistochemistry Percent B-SG Positive Fibers

    Time frame: Baseline, Day 60

07

Study locations

1 site
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
08

References and documents

Publications

  • Mendell JR, Pozsgai ER, Lewis S, Griffin DA, Lowes LP, Alfano LN, Lehman KJ, Church K, Reash NF, Iammarino MA, Sabo B, Potter R, Neuhaus S, Li X, Stevenson H, Rodino-Klapac LR. Gene therapy with bidridistrogene xeboparvovec for limb-girdle muscular dystrophy type 2E/R4: phase 1/2 trial results. Nat Med. 2024 Jan;30(1):199-206. doi: 10.1038/s41591-023-02730-9. Epub 2024 Jan 4. PubMed 38177855 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2018 to primary completion in Jan 2025, 74 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2018
First posted
Aug 29, 2018
StartActual
Oct 27, 2018
Primary completionActual
Jan 14, 2025
CompletionActual
Jan 14, 2025
Results delay requested
Jan 12, 2026
Last update
Jan 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03652259
Responsible party
Sponsor
First posted
Aug 29, 2018
Start date
Oct 27, 2018
Primary completion
Jan 14, 2025
Completion
Jan 14, 2025
Last update
Jan 20, 2026

Study contacts

Medical Director
study director · Sarepta Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion